Eterna Therapeutics Inc (ERNA)

Dec 24, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World

Dec 24, 2024

Dec 18, 2024

ERNA stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada

Dec 18, 2024

Dec 11, 2024

Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - The Eastern Progress Online

Dec 11, 2024

Dec 08, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World

Dec 08, 2024

Dec 04, 2024

Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online

Dec 04, 2024

Dec 04, 2024

Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada

Dec 04, 2024

Dec 03, 2024

Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire

Dec 03, 2024

Dec 03, 2024

Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research - StockTitan

Dec 03, 2024

Dec 02, 2024

ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia

Dec 02, 2024

Nov 26, 2024

Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa

Nov 26, 2024

Nov 25, 2024

Eterna Therapeutics initiates $1 million stock buyback - Investing.com India

Nov 25, 2024

Nov 25, 2024

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program - GlobeNewswire

Nov 25, 2024

Nov 24, 2024

StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Nov 24, 2024

Nov 23, 2024

ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges - Investing.com Australia

Nov 23, 2024

Nov 22, 2024

ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 16, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World

Nov 16, 2024

Nov 15, 2024

ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India

Nov 15, 2024

Nov 14, 2024

Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com

Nov 14, 2024

Nov 14, 2024

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times

Nov 14, 2024

Nov 14, 2024

Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat

Nov 14, 2024

Nov 07, 2024

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - Business Wire

Nov 07, 2024

Nov 05, 2024

Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com

Nov 05, 2024

Nov 05, 2024

Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK

Nov 05, 2024

Nov 01, 2024

NTN Buzztime Enters Into Material Definitive Agreement and Reports Voting Results at Annual Meeting Eterna Therapeutics Inc., a company listed on the Nasdaq Stock Market under the symbol ERNA, recently filed a Form 8-K with the Securities - Defense World

Nov 01, 2024

Oct 30, 2024

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire

Oct 30, 2024

Oct 29, 2024

Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Eterna Therapeutics announces share issuance and executive agreements - Investing.com India

Oct 29, 2024

Oct 18, 2024

Eterna, Factor announce license, collaboration agreement - Yahoo Finance

Oct 18, 2024

Oct 17, 2024

Eterna secures exclusive license for cell therapy tech - Investing.com India

Oct 17, 2024

Oct 17, 2024

Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK

Oct 17, 2024

Oct 17, 2024

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire

Oct 17, 2024

Oct 06, 2024

Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com

Oct 06, 2024

Oct 01, 2024

Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World

Oct 01, 2024

Sep 27, 2024

Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com

Sep 27, 2024

Sep 27, 2024

Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks

Sep 27, 2024

Sep 27, 2024

Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Sep 27, 2024

Sep 23, 2024

Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

Sep 23, 2024

Sep 23, 2024

Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com

Sep 23, 2024

Sep 23, 2024

Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com

Sep 23, 2024